PULM - Pulmatrix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4610
+0.0281 (+6.4911%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4329
Open0.4232
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4232 - 0.4699
52 Week Range0.4230 - 3.4200
Volume726,250
Avg. Volume813,812
Market Cap18.551M
Beta3.63
PE Ratio (TTM)N/A
EPS (TTM)-0.9320
Earnings DateMay 3, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering
    PR Newswire28 days ago

    Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering

    LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is comprised of one share of common stock (or common stock equivalent), one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock.

  • Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline
    PR Newswirelast month

    Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline

    LEXINGTON, Mass. , March 13, 2018 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary ...

  • Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?

    Investors are always looking for growth in small-cap stocks like Pulmatrix Inc (NASDAQ:PULM), with a market cap of US$31.15M. However, an important fact which most ignore is: how financially healthyRead More...

  • Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire2 months ago

    Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix

    NEW YORK, NY / ACCESSWIRE / January 29, 2018 / All three major indexes closed the week at record highs Friday as corporate earnings continue to impress investors. The Dow Jones Industrial Average gained ...

  • Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
    Simply Wall St.3 months ago

    Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM over the last few months. As aRead More...

  • Zacks Small Cap Research3 months ago

    PULM: MHRA Authorizes CTA; Patient Screening Commences!

    By Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, ...

  • Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
    PR Newswire3 months ago

    Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018

    LEXINGTON, Mass., Jan. 24, 2018 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new preclinical data for Pulmazole (PUR1900), its inhaled antifungal drug, in a poster at the 8th Advances Against Aspergillosis Conference in Lisbon, Portugal. In a preclinical model of invasive aspergillosis, Pulmazole treatment by inhalation resulted in a significant prolongation of survival and improved clinical signs of infection compared to placebo treatment. "The preclinical efficacy data highlights the potential advantages of Pulmazole in treating pulmonary Aspergillus infections by delivering itraconazole directly to the lungs," said David Hava, Ph.D., Chief Scientific Officer for Pulmatrix.

  • Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
    PR Newswire3 months ago

    Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

    ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients.

  • How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
    Simply Wall St.4 months ago

    How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?

    Examining Pulmatrix Inc’s (NASDAQ:PULM) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...

  • Pulmatrix Inc (PULM): Time For A Financial Health Check
    Simply Wall St.5 months ago

    Pulmatrix Inc (PULM): Time For A Financial Health Check

    While small-cap stocks, such as Pulmatrix Inc (NASDAQ:PULM) with its market cap of USD $34.31M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube5 months ago

    Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Pulmatrix, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pulmatrix, Inc. – Regeneron Pharmaceuticals, Inc., Nektar Therapeutics and GlycoMimetics, Inc. (REGN-US, NKTR-US and GLYC-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.34 ... Read more (Read more...)

  • PULM: Business And Financial Update For Third Quarter 2017
    Zacks Small Cap Research5 months ago

    PULM: Business And Financial Update For Third Quarter 2017

    On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry.  Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.

  • Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials
    PR Newswire5 months ago

    Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials

    Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ --  Pulmatrix, Inc . (NASDAQ: PULM) today reports ...

  • Pulmatrix Presents at the North American Cystic Fibrosis Conference
    PR Newswire6 months ago

    Pulmatrix Presents at the North American Cystic Fibrosis Conference

    Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream LEXINGTON, Mass. , Oct. 31, 2017 /PRNewswire/ --  Pulmatrix, ...

  • Pulmatrix Appoints Dr. James Roach as Chief Medical Officer
    PR Newswire6 months ago

    Pulmatrix Appoints Dr. James Roach as Chief Medical Officer

    Dr. Roach will lead the clinical development of Pulmatrix's innovative inhaled drugs for serious lung diseases, including allergic bronchopulmonary aspergillosis (ABPA) and chronic obstructive lung disease (COPD).

  • ACCESSWIRE6 months ago

    Pulmatrix: Company to Watch in Lung Disease Market

    SAN DIEGO, CA / ACCESSWIRE / October 24, 2017 / CEOCFO Magazine , an independent investment publication that highlights important technologies and companies, today focuses on the huge markets for drug ...

  • Is It Time To Buy Pulmatrix Inc (PULM)?
    Simply Wall St.6 months ago

    Is It Time To Buy Pulmatrix Inc (PULM)?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...

  • Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
    PR Newswire7 months ago

    Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

    The FDA designation provides five years of market exclusivity for Pulmatrix's inhaled product for treating fungal infections in the lungs of patients with allergic bronchopulmonary aspergillosis LEXINGTON, ...

  • ACCESSWIRE7 months ago

    Today's Research Reports on Trending Tickers: Opko Health and Pulmatrix

    NEW YORK, NY / ACCESSWIRE / September 27, 2017 / U.S. markets were mixed Tuesday, with the Dow Jones Industrial Average falling for the fourth consecutive session for the first time since June. The Dow ...

  • Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017
    PR Newswire7 months ago

    Pulmatrix to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017

    As part of the presentation, Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix, will provide an update on the Company's business and its pipeline of inhaled therapeutics. The presentation will provide updates on the lead pipeline programs and highlight Pulmatrix's recent in-licensing of narrow spectrum kinase inhibitors (NSKI) from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

  • Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug
    PR Newswire7 months ago

    Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug

    The first new patent expands the potential of Pulmatrix's technology for delivering drugs directly to the lungs. Pulmatrix has developed a dry powder that 'flies' easily through the airways and can deliver a wide range of types of drugs.

  • Is It The Right Time To Buy Pulmatrix Inc (PULM)?
    Simply Wall St.7 months ago

    Is It The Right Time To Buy Pulmatrix Inc (PULM)?

    Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of months onRead More...

  • Zacks Small Cap Research7 months ago

    PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix

    We met with Pulmatrix’s (PULM) management (CFO  Bill Duke) at the Rodman & Renshaw conference held at New York city on September 11th and 12th 2017.  Mr. Duke spoke at length about advancing their two lead product candidates PUR1900 and PUR1800 through clinical studies. PUR1900 has been the subject of an Investigational New Drug application (IND).  Phase 1/1b is a critical milestone establishing PUR1900 safety, tolerability and PK profile versus ABPA-Asthma oral antifungal standard of care (Sporanox).  The clinical plan for Phase 1/1b PUR1900 is a three-part study comprised of single ascending dose (SAD), multiple ascending dose (MAD) as well as single dose comparing inhaled versus oral dose of the drug.  The studies will be conducted in parallel.  The SAD study will recruit six healthy volunteers who will be administered escalating doses of PUR1900 (dose: 5mg, 10mg and 25mg) to assess the safety and tolerability of PUR1900 along with 96h PK profile.  The MAD trail will also recruit six healthy volunteers to study the PK profile, safety and tolerability over a 14 day dosing period (10mg and 20mg).  Part 3 of the Phase 1/1b trial is a cross-over study designed to determine the PK, safety and tolerability of 20mg of PUR1900 (inhaled route) as compared to 200mg of Sporanox (oral route) in twelve asthma patients.